Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer

Hinke Siebinga, Judith olde Heuvel, Erik-Jan Rijkhorst, Jeroen J.M.A. Hendrikx and Berlinda J. de Wit-van der Veen
Journal of Nuclear Medicine January 2023, 64 (1) 63-68; DOI: https://doi.org/10.2967/jnumed.122.264101
Hinke Siebinga
1Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands;
2Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judith olde Heuvel
1Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik-Jan Rijkhorst
3Department of Medical Physics and Technology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeroen J.M.A. Hendrikx
1Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands;
2Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berlinda J. de Wit-van der Veen
1Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 1 63-68
DOI 
https://doi.org/10.2967/jnumed.122.264101
PubMed 
35680416

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication March 4, 2022
  • Revision received June 2, 2022
  • Published online January 4, 2023.

Article Versions

  • previous version (June 9, 2022 - 13:10).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Hinke Siebinga1,2,
  2. Judith olde Heuvel1,
  3. Erik-Jan Rijkhorst3,
  4. Jeroen J.M.A. Hendrikx1,2 and
  5. Berlinda J. de Wit-van der Veen1
  1. 1Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands;
  2. 2Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands; and
  3. 3Department of Medical Physics and Technology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  1. For correspondence or reprints, contact Berlinda J. de Wit-van der Veen (l.vd.veen{at}nki.nl).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 5 Citations
  • 8 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm
    Francesco Collamati, Silvio Morganti, Matthias N. van Oosterom, Lorenzo Campana, Francesco Ceci, Stefano Luzzago, Carlo Mancini-Terracciano, Riccardo Mirabelli, Gennaro Musi, Francesca Nicolanti, Ilaria Orsi, Fijs W. B. van Leeuwen, Riccardo Faccini
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 10
  • Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patients
    Hinke Siebinga, Bastiaan M. Privé, Steffie M. B. Peters, James Nagarajah, Thomas P. C. Dorlo, Alwin D. R. Huitema, Berlinda J. de Wit‐van der Veen, Jeroen J. M. A. Hendrikx
    CPT: Pharmacometrics & Systems Pharmacology 2023 12 8
  • Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa)
    Ruiyue Zhao, Zeheng Xia, Miao Ke, Jie Lv, Huizhen Zhong, Yulu He, Di Gu, Yongda Liu, Guohua Zeng, Lin Zhu, David Alexoff, Hank F. Kung, Xinlu Wang, Tao Sun
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 7
  • A proof of principle study using radiopharmaceuticals to quantify and localize container-content interactions in medical syringes
    C. Dupire, P. Chennell, B. Pereira, N. Courtiol, S. Buj, R. Cueff, S. Crauste-Manciet, V. Sautou, C. Morgat
    Scientific Reports 2023 13 1
  • Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma
    Ryan Kohlbrenner, Xiao Wu, Hao G. Nguyen, Matthew R. Cooperberg, Tushar Chakravarty, Peter R. Carroll, Thomas A. Hope
    Radiology 2024 312 2
  • Predicting the effect of different folate doses on [68Ga]Ga-PSMA-11 organ and tumor uptake using physiologically based pharmacokinetic modeling
    Hinke Siebinga, Jeroen J. M. A. Hendrikx, Alwin D. R. Huitema, Berlinda J. de Wit-van der Veen
    EJNMMI Research 2023 13 1
  • Quantification of biochemical PSA dynamics after radioligand therapy with [177Lu]Lu-PSMA-I&T using a population pharmacokinetic/pharmacodynamic model
    Hinke Siebinga, Berlinda J. de Wit-van der Veen, Daphne M. V. de Vries-Huizing, Wouter V. Vogel, Jeroen J. M. A. Hendrikx, Alwin D. R. Huitema
    EJNMMI Physics 2024 11 1
  • Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling
    Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Marcel P. M. Stokkel, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx
    EJNMMI Physics 2023 10 1

Article usage

Article usage: June 2022 to April 2025

AbstractFullPdf
Jun 20221858056
Jul 202246709
Aug 2022312010
Sep 2022211010
Oct 202216006
Nov 2022140010
Dec 202275015
Jan 202311725463
Feb 20235791726
Mar 2023528515
Apr 2023391512
May 20232661428
Jun 2023304911
Jul 20236022619
Aug 20234233026
Sep 20234327031
Oct 20233513118
Nov 20234213019
Dec 2023656333
Jan 20243917120
Feb 20242021620
Mar 20243212932
Apr 2024406931
May 2024197424
Jun 2024369617
Jul 20249712940
Aug 2024899824
Sep 2024181917
Oct 2024154633
Nov 2024214219
Dec 2024203820
Jan 2025194628
Feb 2025169864
Mar 2025206034
Apr 2025186449
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (1)
Journal of Nuclear Medicine
Vol. 64, Issue 1
January 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer
Hinke Siebinga, Judith olde Heuvel, Erik-Jan Rijkhorst, Jeroen J.M.A. Hendrikx, Berlinda J. de Wit-van der Veen
Journal of Nuclear Medicine Jan 2023, 64 (1) 63-68; DOI: 10.2967/jnumed.122.264101

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer
Hinke Siebinga, Judith olde Heuvel, Erik-Jan Rijkhorst, Jeroen J.M.A. Hendrikx, Berlinda J. de Wit-van der Veen
Journal of Nuclear Medicine Jan 2023, 64 (1) 63-68; DOI: 10.2967/jnumed.122.264101
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
  • Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival
  • Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice
Show more Clinical Investigation

Similar Articles

Keywords

  • PSMA
  • prostate cancer
  • peptide amount
  • receptor saturation
  • specific activity
SNMMI

© 2025 SNMMI

Powered by HighWire